Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Localised adrenocortical carcinoma (ENSAT stage I to III, resectable), drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether adjuvant chemotherapy adds to mitotane in high-risk disease awaits ADIUVO-2.
Mitotane is slow to reach therapeutic levels and causes neurological and gastrointestinal toxicity in many patients.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Adrenal incidentalomas are common and distinguishing early carcinoma from adenoma on imaging is imperfect.
Surgical expertise is concentrated in few centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Five-year recurrence-free survival 79 percent with adjuvant mitotane against 75 percent with surveillance (hazard ratio 0.
A milestone in how this cancer is treated.
Observation with imaging every three months (ADIUVO showed no benefit from mitotane).
Adjuvant mitotane titrated to 14 to 20 mg/L for at least two years with glucocorticoid replacement; tumour-bed radiotherapy after incomplete resection; platinum-based chemotherapy considered for very high-risk tumours (ADIUVO-2).
Hormone work-up, contrast CT or MRI of the adrenal, chest CT and FDG-PET; no biopsy of a resectable adrenal mass; germline testing.